CL2010000998A1 - Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease. - Google Patents

Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease.

Info

Publication number
CL2010000998A1
CL2010000998A1 CL2010000998A CL2010000998A CL2010000998A1 CL 2010000998 A1 CL2010000998 A1 CL 2010000998A1 CL 2010000998 A CL2010000998 A CL 2010000998A CL 2010000998 A CL2010000998 A CL 2010000998A CL 2010000998 A1 CL2010000998 A1 CL 2010000998A1
Authority
CL
Chile
Prior art keywords
disease
compounds
carboxamidine
pyrazolin
psychosis
Prior art date
Application number
CL2010000998A
Other languages
Spanish (es)
Inventor
Loevezijn Arnold Van
Bakker Wouter I Iwema
Axel Stoit
Agatha A M Rensink
Jennifer Venhorst
Der Neut Martina A W Van
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66221066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010000998(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Priority to CL2010000998A priority Critical patent/CL2010000998A1/en
Publication of CL2010000998A1 publication Critical patent/CL2010000998A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de arilsulfonil pirazolin carboxamidina, antagonistas de 5-ht6; proceso de preparación; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento o profilaxis de enfermedades tales como psicosis, epilepsia, enfermedad de Parkinson, migraña y enfermedad de Alzheimer.Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, Parkinson's disease, migraine and Alzheimer's disease.

CL2010000998A 2010-09-22 2010-09-22 Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease. CL2010000998A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2010000998A CL2010000998A1 (en) 2010-09-22 2010-09-22 Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2010000998A CL2010000998A1 (en) 2010-09-22 2010-09-22 Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease.

Publications (1)

Publication Number Publication Date
CL2010000998A1 true CL2010000998A1 (en) 2011-03-11

Family

ID=66221066

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000998A CL2010000998A1 (en) 2010-09-22 2010-09-22 Compounds derived from arylsulfonyl pyrazolin carboxamidine, 5-ht6 antagonists; Preparation process; intermediary compounds; pharmaceutical composition; and its use for the treatment or prophylaxis of diseases such as psychosis, epilepsy, parkinson's disease, migraine and Alzheimer's disease.

Country Status (1)

Country Link
CL (1) CL2010000998A1 (en)

Similar Documents

Publication Publication Date Title
PH12016501570A1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
PH12016501791A1 (en) Muscarinic receptor agonists
CL2009000650A1 (en) Compounds derived from amino-pyrazine, kinase-pi 3 inhibitors; pharmaceutical composition; and use for the treatment of inflammatory or allergic conditions, such as respiratory diseases, rheumatoid arthritis, ulcerative colitis, among others.
TN2015000250A1 (en) Novel benzimidazole derivatives as ep4 antagonists
CL2012001073A1 (en) Compounds derived from pyrido [4,3-d] pyrimidin-5-one, their pharmaceutical compositions and their use as kinase inhibitors to treat asthma, COPD, ulcerative colitis, bronchitis, lupus, breast cancer, Alzheimer's disease, Alzheimer's disease parkinson's, osteoporosis, multiple sclerosis, diabetes, eye disorders, restenosis, inflammatory diseases.
DOP2014000115A (en) USE OF SUBSTITUTED 4-PHENYL-PYRIDINS FOR THE MANUFACTURE OF USEFUL MEDICINES IN THE TREATMENT OF DISEASES RELATED TO THE NK1 RECEIVER
UY31619A1 (en) ESPIRO COMPOUNDS AS ANTAGONISTS OF THE NPY Y5 RECEIVER
BR112012013431A2 (en) compound, pharmaceutical composition and its use
GT201300122A (en) ANTIGONISTS OF THE RECEIVER OF THE CGRP OF PIPERIDINONA CARBOXAMIDA AZAINDANO
CL2014000806A1 (en) Compounds derived from 1-arylcarbonyl-4-oxy-piperidino; pharmaceutical composition that includes them; Use for the prevention or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease or multiple sclerosis.
GB2511685A (en) Muscarinic m1 receptor agonists
MX2011009847A (en) Anthelmintic agents and their use.
CL2016002091A1 (en) Triazine compound and its use for medicinal purposes
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX351305B (en) Mineralocorticoid receptor antagonists.
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
NZ731118A (en) Dopamine d3 receptor antagonists compounds
MY201535A (en) Therapeutic compounds
UA117154C2 (en) S1p3 antagonists
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
CL2015001881A1 (en) Compound 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohexyl-3-en-1-carbaldehyde; use of the compound for the treatment of Alzheimer's disease; pharmaceutical composition; Method to prepare the composition.
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions